Clinical Trial Update: Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 clinical trial evaluating ACAM-CDIFF, a Clostridium difficile toxoid vaccine, in subjects with Clostridium dif…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• ACAM-CDIFF

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diarrhea, Clostridium Difficile Infection | Phase 2 | Status: COMPLETED